Extended Data Fig. 8: The combination of lenvatinib and gefitinib suppresses tumour growth and extends survival time in HCC PDX mouse models in vivo. | Nature

Extended Data Fig. 8: The combination of lenvatinib and gefitinib suppresses tumour growth and extends survival time in HCC PDX mouse models in vivo.

From: EGFR activation limits the response of liver cancer to lenvatinib

Extended Data Fig. 8

ab, Four HCC PDX models were established and examined for EGFR expression by IHC analyses. a, Representative images of H&E and EGFR staining in the four PDX models. Scale bars, 50 μm. b, H-score of EGFR expression levels in the four PDX models. Data are mean ± s.e.m., n = 5 samples. cn, After tumour establishment (~200 mm3), mice were treated with vehicle, lenvatinib (4 mg kg−1), gefitinib (80 mg kg−1) or lenvatinib (4 mg kg−1) plus gefitinib (80 mg kg−1). cf, Growth curves of four HCC PDX models in mice treated with vehicle, lenvatinib, gefitinib or their combination. n = 5 mice per group. Data are mean ± s.e.m. P values were determined by two-way ANOVA with Tukey multiple comparisons. gj, Kaplan–Meier survival curves of the PDX models after the indicated treatments. n = 5 mice per group. P values were determined by log-rank Mantel–Cox test. kn, Body weights of mice in the PDX models with the aforementioned treatments were assessed. n = 5 mice per group. Data are mean ± s.e.m

Source data.

Back to article page